abe 17 2011
Paro y recortes
En el mes de noviembre el paro ha disminuido en Erandio en 11 hombres y 7 mujeres.
Desde primeros de año el aumento ha sido de 69 hombres y 105 mujeres.
El Ayuntamiento de Erandio oferta el siguiente empleo temporal:
- 3 auxiliares domiciliarias
- 1 auxiliar administrativo/a
- 6 peones de obra
- 1 encargado/a de obra
- 8 monitores/as de tiempo libre
6 meses para 19 personas, pero en Erandio hay 1.812 personas desempleadas y el PNV presenta unos presupuestos de mas de 35 millones de euros en los que las áreas de urbanismo y policía municipal son las que mas dinero se llevan.
Sueldo del Alcalde 72.000 euros, dos personas de confianza a sueldo pagado por todas y todos los erandioztarrak casi 107.000€ anuales, un concejal a jornada completa otros casi 60.000€ un concejal y una concejala a jornada parcial, con un costo por ambos de 63.000€
Claro que la propuesta de ahorro pasa por bajar el gasto en cultura de 60.000€ a 30.000€, el gasto de actividades deportivas de 110.000€ a 30.000€ y en el area de igualdad de 89.300€ a 53.000€
Siempre nos quedarán los 500.000€ para “mover” la biblioteca de Altzaga (que no se va a mover) o 200.000€ para el Plan General de Ordenación Urbana (15 años sin hacer), para poder gastar 600.000€ en jardinería, 600.000€ en una carretera que parta por la mitad Goiherri y La Campa; 710.000€ para la conexión peatonal Altzaga-Kukularra…
En definitiva, cultua, euskara, juventud, deportes, empleo, igualdad, ayuda social, no son los objetivos del Ayuntamiento de Erandio o lo son menos que la aportación que recbe un sólo concejal para trabajos sin planificación al que se le asignan 230.000€
Información Bitacoras.com…
Valora en Bitacoras.com: En el mes de noviembre el paro ha disminuido en Erandio en 11 hombres y 7 mujeres. Desde primeros de año el aumento ha sido de 69 hombres y 105 mujeres. El Ayuntamiento de Erandio oferta el siguiente empleo temporal: 3 auxili….
… [Trackback] …
[...] Read More on that Topic: erandio.euskoalkartasuna.net [...] …
… [Trackback] …
[...] There you can find 16566 more Info on that Topic: erandio.euskoalkartasuna.net [...] …
… [Trackback] …
[...] There you can find 51326 more Info to that Topic: erandio.euskoalkartasuna.net [...] …
… [Trackback] …
[...] Read More on to that Topic: erandio.euskoalkartasuna.net [...] …
… [Trackback] …
[...] Read More on that Topic: erandio.euskoalkartasuna.net [...] …
… [Trackback] …
[...] Find More Info here on that Topic: erandio.euskoalkartasuna.net [...] …
… [Trackback] …
[...] Find More Information here on that Topic: erandio.euskoalkartasuna.net [...] …
… [Trackback] …
[...] Read More Information here to that Topic: erandio.euskoalkartasuna.net [...] …
… [Trackback] …
[...] Read More Information here to that Topic: erandio.euskoalkartasuna.net [...] …
… [Trackback] …
[...] Read More to that Topic: erandio.euskoalkartasuna.net [...] …
… [Trackback] …
[...] There you can find 73753 more Information to that Topic: erandio.euskoalkartasuna.net [...] …
… [Trackback] …
[...] Read More on that Topic: erandio.euskoalkartasuna.net [...] …
… [Trackback] …
[...] Find More on that Topic: erandio.euskoalkartasuna.net [...] …
… [Trackback] …
[...] Here you will find 67054 additional Information on that Topic: erandio.euskoalkartasuna.net [...] …
… [Trackback] …
[...] Information to that Topic: erandio.euskoalkartasuna.net [...] …
where can i purchase steroids
References:
pad.stuve.uni-ulm.de
best muscle gain stacks
References:
duvidas.construfy.com.br
what steroids are legal in the united states
References:
sorucevap.kodmerkezi.net
anabolic pre workout
References:
notes.io
whats better dbol or anadrol
References:
http://www.zamsh.com
common anabolic steroids
References:
http://www.anibookmark.com
pro muscle 100 shredded stack
References:
nephila.org
how many different types of steroids are there
References:
schoolido.lu
what is the best steroid stack
References:
templeton-high.mdwrite.net
steroids after effects
References:
http://www.udrpsearch.com
what are the two main types of steroids
References:
matkafasi.com
gnc supplements with steroids
References:
travelersqa.com
anabolic steroid online shop
References:
badcase.org
Ipamorelin has attracted attention in both clinical and research settings
for its ability to stimulate growth hormone secretion without
the same level of side effects seen with other analogues.
While short‑term studies show promising benefits for muscle mass, bone density,
and overall vitality, the long‑term safety profile remains a subject of ongoing investigation.
Side Effects of Ipamorelin in Growth Hormone Release and Anti‑Aging Research
In controlled trials that measure growth hormone release,
participants who received ipamorelin experienced mild elevations in circulating insulin-like growth factor 1 (IGF‑1).
IGF‑1 is a key mediator of many anabolic processes but also carries the
potential to influence cell proliferation pathways.
Over prolonged periods, some users have reported increased
hunger, mild fluid retention, and occasional joint discomfort that may be linked to altered cartilage metabolism.
The hormone’s selective action on growth hormone secretion limits stimulation of other pituitary axes; nevertheless, chronic exposure can lead to subtle
changes in metabolic regulation, such as variations in glucose tolerance or
lipid profiles. In anti‑aging studies, where doses are often administered over months or years, researchers have noted a small rise in the incidence of
benign thyroid nodules and mild increases in blood pressure among participants with pre‑existing hypertension. These
findings underscore that while ipamorelin’s side effect spectrum is narrower than some
older growth hormone secretagogues, vigilance remains essential
for long‑term use.
What is Ipamorelin?
Ipamorelin is a synthetic pentapeptide that functions as a selective growth hormone releasing hormone (GHRH) analogue.
Its primary mechanism involves binding to the GHRH receptor on pituitary somatotroph cells, thereby prompting the release of endogenous growth
hormone into the bloodstream. Unlike other secretagogues such as ghrelin mimetics or analogues
that can activate multiple receptors, ipamorelin’s activity is highly specific, which contributes to its favorable safety profile in many clinical contexts.
The peptide is commonly administered via subcutaneous injection and is available in various concentrations for research and therapeutic purposes.
Chemical Nature and Classification
Chemically, ipamorelin consists of five amino acid residues:
proline, threonine, glycine, lysine, and an N‑terminal pyroglutamic acid.
The sequence is abbreviated as Phe–Trp–Gly–His–Val
in its active form, though the precise stereochemistry confers resistance to proteolytic enzymes, extending its half‑life relative to other short peptides.
It belongs to the class of synthetic growth hormone
secretagogues that mimic natural GHRH but with enhanced potency and selectivity.
In pharmaceutical classifications, ipamorelin is listed under peptide hormones and is not yet approved by major
regulatory agencies for routine clinical use; it remains primarily
a tool in research laboratories and a subject of investigative
trials aimed at elucidating its long‑term effects
on endocrine function and tissue regeneration.
Long‑Term Considerations
Because growth hormone influences numerous downstream targets, sustained elevation—whether through chronic ipamorelin administration or other means—has the potential to disrupt homeostatic balances.
The risk of hyperinsulinemia, insulin resistance, and alterations in adipose tissue
distribution has been documented in animal models exposed to
prolonged GHRH analogue therapy. Additionally, increased IGF‑1 levels may theoretically enhance the
growth rate of pre‑existing neoplastic cells, raising concerns about carcinogenesis over
decades of use. Although human data are limited, these mechanistic insights
suggest that long‑term ipamorelin therapy should be approached with caution, particularly in populations with a history of cancer or metabolic
disorders.
Monitoring and Mitigation Strategies
To mitigate potential adverse outcomes, clinicians and researchers
recommend periodic assessment of endocrine panels, including IGF‑1, fasting glucose, lipid profiles,
thyroid function tests, and blood pressure measurements. Imaging studies such as ultrasound or
MRI may be warranted if thyroid nodules develop or if there is clinical suspicion of other organ involvement.
Dose titration based on individual response rather than a fixed regimen can help maintain growth hormone within physiologic ranges, thereby reducing the likelihood of side effects.
In summary, ipamorelin’s role as a selective GHRH analogue offers distinct advantages in stimulating growth hormone
release with fewer off‑target actions compared to older analogues.
Nevertheless, its long‑term safety profile is not fully
established, and current evidence points to possible
metabolic, cardiovascular, and endocrine sequelae that warrant careful monitoring.
Continued research and longitudinal studies are essential to
delineate the balance between therapeutic benefits and potential risks associated with extended ipamorelin use.
References:
valley md
least harmful steroids
References:
mardplay.com
… [Trackback] …
[...] Find More on on that Topic: erandio.euskoalkartasuna.net [...] …